Cart
sales@molnova.com
Home - Products - Others - Other Targets - Ald-Ph-NHS ester

Ald-Ph-NHS ester

CAS No. 60444-78-2

Ald-Ph-NHS ester( —— )

Catalog No. M26878 CAS No. 60444-78-2

Ald-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 40 In Stock
25MG 65 In Stock
50MG 87 In Stock
100MG 143 In Stock
200MG 223 In Stock
500MG 385 In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Ald-Ph-NHS ester
  • Note
    Research use only, not for human use.
  • Brief Description
    Ald-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).
  • Description
    Ald-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    factor D
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    60444-78-2
  • Formula Weight
    247.206
  • Molecular Formula
    C12H9NO5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (404.53 mM)
  • SMILES
    O=Cc1ccc(cc1)C(=O)ON1C(=O)CCC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.GADHACHANDA VR, et, al. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders. WO2015130838A1.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • 26-Dihydroxypyridine...

    26-Dihydroxypyridine hydrochloride is used as a reagent to synthesize uridine phosphorylase inhibitors that increase Uridine (Urd) (U829910) levels.

  • URAT1 inhibitor 7

    URAT1 inhibitor 7 is a novel and potent inhibitor of the human uric acid transporter protein URAT1 (IC50:12 nM).URAT1 inhibitor 7 inhibits CYP2C9 with an IC50 of 4.2 μM.URAT1 inhibitor 7 can be used to study hyperuricemia and gout.

  • Glenzocimab

    Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.

Sign In Join Free